TY - JOUR
T1 - Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation
AU - Onishi, Yasushi
AU - Mori, Shin Ichiro
AU - Kusumoto, Shigeru
AU - Sugimoto, Kyoko
AU - Akahane, Daigo
AU - Morita-Hoshi, Yuriko
AU - Kim, Sung Won
AU - Fukuda, Takahiro
AU - Heike, Yuji
AU - Tanosaki, Ryuji
AU - Tobinai, Kensei
AU - Takaue, Yoichi
PY - 2007/4
Y1 - 2007/4
N2 - We investigated the feasibility of reduced-intensity conditioning with 4 Gy total body irradiation, fludarabine (30 mg/m2 for 6 days), and busulfan (4 mg/kg for 2 days) for bone marrow transplantation from a serologically HLA-matched unrelated donor. Seventeen adult patients (median age, 55 years; range, 27-67 years) with various hematologic malignancies (6 in remission, 11 not in remission) were treated. Successful engraftment was achieved in all patients at a median of day 18 (range, day 14-35) after transplantation, although subsequent secondary graft failure was observed in 2 patients. The cumulative incidence of acute graft-versus-host disease (GVHD) of grades II to IV at day 100 was 48%. With a median follow-up of 286 days (range, 56-687 days), the rates of 1-year overall survival, 100-day nonrelapse mortality, and 1-year nonrelapse mortality were 41%, 14%, and 46%, respectively. Eleven patients died, and the causes of death were relapse (n = 4), pulmonary complications (n = 4), acute GVHD (n = 2), and sepsis (n = 1). The remaining 6 patients (at transplantation, 2 were in remission, and 4 were not in remission) are currently still in remission. These results suggest that this regimen reduces the risk of graft failure, but further studies are needed to ameliorate transplantation-related toxicities, primarily GVHD and/or pulmonary complications.
AB - We investigated the feasibility of reduced-intensity conditioning with 4 Gy total body irradiation, fludarabine (30 mg/m2 for 6 days), and busulfan (4 mg/kg for 2 days) for bone marrow transplantation from a serologically HLA-matched unrelated donor. Seventeen adult patients (median age, 55 years; range, 27-67 years) with various hematologic malignancies (6 in remission, 11 not in remission) were treated. Successful engraftment was achieved in all patients at a median of day 18 (range, day 14-35) after transplantation, although subsequent secondary graft failure was observed in 2 patients. The cumulative incidence of acute graft-versus-host disease (GVHD) of grades II to IV at day 100 was 48%. With a median follow-up of 286 days (range, 56-687 days), the rates of 1-year overall survival, 100-day nonrelapse mortality, and 1-year nonrelapse mortality were 41%, 14%, and 46%, respectively. Eleven patients died, and the causes of death were relapse (n = 4), pulmonary complications (n = 4), acute GVHD (n = 2), and sepsis (n = 1). The remaining 6 patients (at transplantation, 2 were in remission, and 4 were not in remission) are currently still in remission. These results suggest that this regimen reduces the risk of graft failure, but further studies are needed to ameliorate transplantation-related toxicities, primarily GVHD and/or pulmonary complications.
KW - Busulfan
KW - Fludarabine
KW - TBI
KW - Unrelated donor bone marrow transplantation
UR - http://www.scopus.com/inward/record.url?scp=34247571477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247571477&partnerID=8YFLogxK
U2 - 10.1532/IJH97.06199
DO - 10.1532/IJH97.06199
M3 - Article
C2 - 17483064
AN - SCOPUS:34247571477
SN - 0925-5710
VL - 85
SP - 256
EP - 263
JO - International journal of hematology
JF - International journal of hematology
IS - 3
ER -